Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
fda
8
×
national blog main
national top stories
8
×
venture capital
8
×
boston blog main
texas blog main
texas top stories
biotech
life sciences
san francisco blog main
san francisco top stories
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
national
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
startups
wisconsin blog main
wisconsin top stories
ipo
novartis
vc
biogen
cancer
clinical trials
deals
funding
medical devices
scott gottlieb
What
bio
roundup
ipo
therapeutics
covid
fda
help
medicines
million
new
treat
years
acquisitions
activity
ahead
allogene
analytics
announced
approvals
asco
based
better
big
biofourmis
biogen
biopharma
branded
cancer
candidate
car
catch
celgene
ceo
choices
clamped
close
collabs
colleagues
commissioner
company
Language
unset
Current search:
fda
×
" venture capital "
×
" national top stories "
×
@xconomy.com
3 years ago
Biofourmis Hauls In $100M to Scale Digital Therapeutics Globally
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
5 years ago
Bio Roundup: Generic Drugs Graft, ASCO Ahead, ElevateBio Rises & More
@xconomy.com
5 years ago
DermaClip Ramps Up for U.S. Sales Push of Wound-Healing Device
@xconomy.com
5 years ago
Bio Roundup: $74B for Celgene, Two CAR-T Tales, Ready for SF & More
@xconomy.com
5 years ago
Delivery Robots in Big D, Rodriguez Leaves the Station, & More TX Tech
@xconomy.com
5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More